The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes

Rheumatology (Oxford). 2003 Jan;42(1):89-96. doi: 10.1093/rheumatology/keg038.


Objectives: To investigate the effects of the active metabolite of leflunomide, A77 1726, on fibroblast-like synoviocytes. In rheumatoid arthritis (RA) synoviocytes participate in tissue destruction by producing metalloproteinases (MMP), prostaglandin E(2) (PGE(2)) and interleukin (IL) 6, which are involved in extracellular matrix degradation, resorption of the mineral phase and osteoclast-mediated bone resorption.

Methods: Human synoviocytes were stimulated with IL-1alpha or tumour necrosis factor alpha (TNF-alpha) in the presence of A77 1726. Culture supernatants were analysed for production of interstitial collagenase (MMP-1), tissue-inhibitor of metalloproteinases 1 (TIMP-1), PGE(2) and IL-6. Total RNA was isolated and analysed for steady-state levels of MMP-1, cyclooxygenase-2 (COX-2) and IL-6 mRNA.

Results: A77 1726 inhibited the production of PGE(2) in synoviocytes activated by TNF-alpha and IL-1alpha with median inhibitory concentrations (IC(50)) of 7 and 3 microM respectively. In contrast, MMP-1 and IL-6 production was inhibited at high A77 1726 concentrations (> 10 microM), whereas TIMP-1 was not affected. The inhibition of MMP-1 and IL-6 production was due to the known inhibitory effect of A77 1726 on pyrimidine synthesis, as it was reversed by the addition of uridine. This did not apply to PGE(2) production, which was inhibited via direct action of A77 1726 on COX-2, as shown by the increasing amount of substrate (arachidonic acid) in the culture medium.

Conclusion: This study shows that some of the beneficial effect of leflunomide in RA patients may be due to the inhibition of PGE(2), IL-6 and MMP-1 production in synoviocytes. This effect, coupled with its multiple inhibitory effects on T lymphocyte functions, might account for the significant reduction in the rate of disease progression in RA patients treated with leflunomide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aniline Compounds / pharmacology*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Arachidonic Acid / pharmacology
  • Arthritis, Rheumatoid / metabolism*
  • Cells, Cultured
  • Crotonates
  • Cyclooxygenase 2
  • Dinoprostone / antagonists & inhibitors*
  • Dinoprostone / genetics
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Glyceraldehyde-3-Phosphate Dehydrogenases / metabolism
  • Humans
  • Hydroxybutyrates / pharmacology*
  • Interleukin-6 / antagonists & inhibitors*
  • Interleukin-6 / genetics
  • Isoenzymes / metabolism
  • Matrix Metalloproteinase 1 / genetics
  • Matrix Metalloproteinase Inhibitors*
  • Membrane Proteins
  • Nitriles
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Pyrimidines / metabolism
  • RNA, Messenger / analysis
  • Synovial Membrane / drug effects
  • Synovial Membrane / metabolism*
  • Toluidines
  • Uridine / pharmacology


  • Aniline Compounds
  • Anti-Inflammatory Agents, Non-Steroidal
  • Crotonates
  • Enzyme Inhibitors
  • Hydroxybutyrates
  • Interleukin-6
  • Isoenzymes
  • Matrix Metalloproteinase Inhibitors
  • Membrane Proteins
  • Nitriles
  • Pyrimidines
  • RNA, Messenger
  • Toluidines
  • teriflunomide
  • Arachidonic Acid
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Glyceraldehyde-3-Phosphate Dehydrogenases
  • Matrix Metalloproteinase 1
  • Dinoprostone
  • pyrimidine
  • Uridine